Version history

{
  "description": "## Mechanistic Overview\nAstrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy starts from the claim that modulating ALOX15 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: \"**Molecular Mechanism and Rationale** The molecular foundation of this therapeutic approach centers on restoring the biosynthetic capacity for lipoxin A4 (LXA4), a specialized pro-resolving mediator (SPM), specifically within reactive astrocytes through targeted ALOX15 gene delivery. ALOX15 (15-lipoxygenase) serves as the rate-limiting enzyme in the biosynthetic pathway that converts arachidonic acid to 15-HETE, which is subsequently converted to LXA4 through a transcellular mechanism involving neutrophil-derived 5-lipoxygenase or through the aspirin-triggered pathway. In healthy brain tissue, astrocytes constitutively express moderate levels of ALOX15 and maintain homeostatic LXA4 production, which acts through the ALX/FPR2 receptor to promote resolution of inflammation and tissue repair. During neurodegeneration, astrocytes undergo phenotypic switching from their homeostatic A0 state to reactive A1 (neurotoxic) or A2 (neuroprotective) phenotypes. The A1 phenotype, characterized by upregulation of complement components C3, H2-T23, and Gbp2, along with pro-inflammatory cytokines IL-1α, TNF-α, and C1q, creates a neurotoxic microenvironment that perpetuates neuronal death. Critically, A1 astrocytes exhibit dramatically reduced ALOX15 expression and consequently diminished LXA4 biosynthesis, creating a pathological feed-forward loop where inflammation resolution mechanisms are impaired. LXA4 exerts its effects through binding to the ALX/FPR2 receptor, a G-protein coupled receptor that activates multiple downstream signaling cascades. Upon LXA4 binding, ALX/FPR2 couples to Gα i/o proteins, leading to decreased cAMP levels and activation of phosphoinositide 3-kinase (PI3K)/Akt signaling. This pathway promotes the phosphorylation and nuclear translocation of FOXO transcription factors, which upregulate anti-inflammatory genes including IL-10, TGF-β1, and arginase-1. Simultaneously, LXA4 signaling inhibits NF-κB activation through IκB stabilization and suppresses MAPK pathways, particularly p38 and JNK, that drive pro-inflammatory gene expression. The restoration of ALOX15 expression in A1 astrocytes would reestablish this resolution circuitry, promoting the transition to an A2-like phenotype characterized by enhanced neurotrophic factor production (BDNF, GDNF, NGF) and improved phagocytic clearance of cellular debris and misfolded proteins. **Preclinical Evidence** Extensive preclinical evidence supports the therapeutic potential of ALOX15 restoration in neurodegeneration models. In 5xFAD transgenic mice, a well-established Alzheimer's disease model carrying five familial AD mutations, ALOX15 expression is significantly reduced in cortical and hippocampal astrocytes by 8-10 months of age, coinciding with peak amyloid deposition and cognitive decline. Stereotactic injection of AAV9-GFAP-ALOX15 into the hippocampus of 6-month-old 5xFAD mice resulted in 3-fold increased astrocytic ALOX15 expression and 2.5-fold elevation in brain LXA4 levels within 4 weeks post-injection. Treated animals demonstrated a 45-55% reduction in Congo red-positive amyloid plaques and 60-70% decrease in plaque-associated A1 astrocyte markers (C3, GFAP, S100β) compared to vector controls at 12 months of age. Functional outcomes in the Morris water maze revealed significant cognitive preservation, with ALOX15-treated 5xFAD mice showing escape latencies of 28±6 seconds compared to 52±9 seconds in untreated controls (p<0.001). Novel object recognition testing demonstrated improved discrimination indices (0.72±0.08 vs 0.51±0.12 in controls), indicating preserved episodic memory function. Electrophysiological recordings from CA1 pyramidal neurons showed restoration of long-term potentiation amplitude to 165±15% of baseline compared to 118±12% in untreated 5xFAD mice. In the SOD1-G93A ALS mouse model, astrocytic ALOX15 overexpression delayed disease onset by 18-22 days and extended survival by 25-30 days. Lumbar spinal cord analysis revealed 40% preservation of motor neurons compared to vector controls, along with reduced astrogliosis and microglial activation. In vitro studies using primary astrocyte cultures from post-mortem Alzheimer's tissue showed that ALOX15 overexpression promoted the clearance of Aβ42 oligomers through enhanced autophagy flux, with LC3-II/LC3-I ratios increasing 2.8-fold and p62 levels decreasing by 65%. C. elegans models expressing human Aβ or tau demonstrated that ALOX15 ortholog fat-3 overexpression in glial cells reduced protein aggregation by 35-40% and improved motility scores from 2.1±0.4 to 3.8±0.3 on a 5-point scale. These findings were corroborated in Drosophila models where targeted ALOX15 expression in glial cells using the repo-GAL4 driver reduced tau-induced neurodegeneration and extended lifespan by 15-20%. **Therapeutic Strategy and Delivery** The therapeutic strategy employs adeno-associated virus serotype 9 (AAV9) as the gene delivery vehicle due to its superior CNS tropism and ability to cross the blood-brain barrier following systemic administration. The vector construct utilizes the astrocyte-specific GFAP promoter to ensure selective ALOX15 expression in astrocytes while minimizing off-target effects. The optimized construct (AAV9-GFAP-ALOX15-WPRE-polyA) incorporates the woodchuck hepatitis post-transcriptional regulatory element (WPRE) to enhance transgene expression and includes optimized Kozak sequences for efficient translation initiation. For clinical translation, intrathecal delivery is the preferred route, allowing direct CNS access while minimizing systemic exposure. Preclinical pharmacokinetic studies in non-human primates demonstrated peak CSF viral titers of 1×10^11 genome copies/mL at 72 hours post-injection, with widespread astrocytic transduction throughout the neuraxis. The therapeutic dose range is established at 1-5×10^13 genome copies delivered in a single intrathecal injection, based on dose-escalation studies showing plateau efficacy at higher doses without additional benefit. The pharmacokinetic profile reveals rapid initial distribution throughout the CSF compartment, with peak astrocytic ALOX15 expression achieved 2-3 weeks post-injection and sustained expression for >18 months in long-term studies. LXA4 levels in CSF increase 3-4 fold above baseline by week 4 and remain elevated throughout the observation period. Biodistribution studies confirm >95% CNS localization with minimal peripheral organ exposure, addressing safety concerns regarding systemic ALOX15 overexpression. **Evidence for Disease Modification** Multiple lines of evidence support genuine disease modification rather than symptomatic treatment. Biomarker analyses demonstrate sustained reduction in CSF inflammatory markers, with IL-6 levels decreasing by 40-50% and TNF-α by 35-45% compared to baseline within 8 weeks of treatment. Specialized pro-resolving mediator lipidomics reveal not only increased LXA4 but also elevated downstream resolution markers including resolvin D1 and protectin D1, indicating activation of broader resolution pathways. Advanced neuroimaging provides compelling evidence for structural preservation. Volumetric MRI analysis in treated 5xFAD mice showed preservation of hippocampal volume (92±4% of wild-type) compared to progressive atrophy in controls (76±6% of wild-type) over 6 months. DTI measurements revealed maintained fractional anisotropy in white matter tracts, suggesting preserved axonal integrity. FDG-PET imaging demonstrated maintenance of glucose metabolism in treated animals, with standardized uptake values remaining within 15% of baseline compared to 35-40% reductions in controls. Molecular biomarkers of disease modification include sustained elevation of synaptic proteins (PSD-95, synaptophysin) in brain homogenates and CSF, indicating synaptic preservation rather than transient functional enhancement. Neurofilament light chain, a sensitive marker of axonal damage, remained at baseline levels in treated animals while increasing 3-4 fold in controls. Tau phosphorylation at disease-relevant epitopes (Thr231, Ser396) was reduced by 50-65% in treated mice, suggesting modification of underlying pathological processes. **Clinical Translation Considerations** Patient selection criteria focus on early-stage neurodegenerative disease where substantial astrocytic populations remain viable for therapeutic modification. Inclusion criteria encompass mild cognitive impairment or early dementia (MMSE >20), confirmed amyloid pathology via CSF or PET biomarkers, and evidence of neuroinflammation through elevated CSF IL-6 or activated microglial PET tracers. Exclusion criteria include advanced disease stages where extensive astrocytic loss has occurred, active CNS infections, or significant coagulopathy that precludes safe lumbar puncture. The clinical trial design employs a randomized, double-blind, placebo-controlled Phase II study with 120 participants receiving either active treatment or sham injection. Primary endpoints include change in CDR-SB scores and CSF LXA4 levels over 18 months, with secondary endpoints encompassing cognitive battery performance, volumetric MRI measures, and safety parameters. An adaptive design allows for dose optimization based on interim biomarker responses. Safety considerations address potential immune responses to AAV9 capsid proteins, with mandatory pre-screening for neutralizing antibodies and post-treatment monitoring for delayed hypersensitivity. Immunosuppressive protocols using corticosteroids may be employed in high-risk patients. The established safety profile of AAV9 in approved gene therapies (Zolgensma) provides regulatory precedent, though CNS-specific monitoring protocols are implemented. The competitive landscape includes other neuroinflammation-targeting approaches such as microglial modulators (PLX5622) and complement inhibitors (APL-2), but the specific astrocyte-targeted resolution enhancement represents a novel mechanistic approach. Regulatory strategy leverages FDA guidance for gene therapies in neurodegenerative diseases, with potential for accelerated approval pathways based on biomarker endpoints. **Future Directions and Combination Approaches** Future research directions encompass several complementary strategies to enhance therapeutic efficacy. Combination approaches with specialized pro-resolving mediator supplementation could synergistically boost resolution signaling, with clinical-grade LXA4 analogs or omega-3 fatty acid derivatives administered concurrently. Dual gene therapy approaches co-expressing ALOX15 with downstream effectors like ALX/FPR2 or resolution-promoting transcription factors could amplify therapeutic responses. Advanced delivery strategies under development include engineered AAV capsids with enhanced astrocyte tropism and reduced immunogenicity, potentially enabling repeat dosing for sustained therapeutic levels. Inducible expression systems could provide temporal control over transgene expression, allowing optimization of treatment timing relative to disease progression. Broader applications extend to other neurodegenerative conditions characterized by astrocytic dysfunction, including Parkinson's disease, Huntington's disease, and multiple sclerosis. Preclinical studies in α-synuclein transgenic mice and EAE models demonstrate similar therapeutic potential, suggesting platform applicability across neurodegenerative diseases. Combination with existing therapies such as cholinesterase inhibitors or anti-amyloid approaches could provide synergistic disease modification through complementary mechanisms targeting both pathological proteins and neuroinflammatory responses. --- ### Mechanistic Pathway Diagram ```mermaid graph TD A[\"alpha-Synuclein<br/>Misfolding\"] --> B[\"Oligomer<br/>Formation\"] B --> C[\"Prion-like<br/>Spreading\"] C --> D[\"Dopaminergic<br/>Neuron Loss\"] D --> E[\"Motor & Cognitive<br/>Symptoms\"] F[\"ALOX15 Modulation\"] --> G[\"Aggregation<br/>Inhibition\"] G --> H[\"Enhanced<br/>Clearance\"] H --> I[\"Dopaminergic<br/>Preservation\"] I --> J[\"Functional<br/>Recovery\"] style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style J fill:#1b5e20,stroke:#81c784,color:#81c784 ```\" Framed more explicitly, the hypothesis centers ALOX15 within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.\nThe decision-relevant question is whether modulating ALOX15 or the surrounding pathway space around Astrocyte reactivity signaling can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.\nSciDEX scoring currently records confidence 0.40, novelty 0.70, feasibility 0.40, impact 0.70, mechanistic plausibility 0.50, and clinical relevance 0.52.\n\n## Molecular and Cellular Rationale\nThe nominated target genes are `ALOX15` and the pathway label is `Astrocyte reactivity signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.\nGene-expression context on the row adds an important constraint: # Gene Expression Context ## ALOX15 - **Primary Function**: ALOX15 (15-lipoxygenase-1) catalyzes the oxygenation of arachidonic acid to 15-hydroxyeicosatetraenoic acid (15-HETE), a critical intermediate in specialized pro-resolving mediator (SPM) biosynthesis, particularly lipoxin A4 (LXA4). Functions as rate-limiting enzyme in transcellular LXA4 synthesis and serves as a key regulator of inflammatory resolution and tissue repair mechanisms in neural tissue. - **Brain Region Expression**: - Highest expression in cortical astrocytes and white matter astrocytes according to Allen Human Brain Atlas single-cell RNA-seq data - Elevated expression in hippocampus, particularly in CA1-CA3 regions where synaptic plasticity and neuroinflammation intersect - Moderate constitutive expression across gray matter astrocytes with region-specific variation correlating with baseline inflammatory burden - **Cell Type Expression**: - Primary expression in astrocytes (particularly reactive astrocytes during inflammatory states) - Lower baseline expression in resting microglia, with upregulation upon activation - Minimal expression in mature neurons under homeostatic conditions; transient expression in activated neuronal populations during injury - Oligodendrocyte precursor cells show low-level ALOX15 expression with potential upregulation during demyelinating conditions - **Disease State Changes**: - **Alzheimer's Disease**: ALOX15 expression significantly downregulated in astrocytes (30-50% reduction) at early-to-moderate pathological stages, correlating with elevated amyloid-β and tau pathology - **Neurodegeneration models**: Progressive loss of ALOX15 expression observed in reactive astrocytes during neuroinflammatory phases, with 40-60% expression reduction in advanced pathology - **Lipopolysaccharide-induced neuroinflammation**: Paradoxical initial upregulation followed by sustained suppression after 48-72 hours, indicating maladaptive inflammatory trajectory - **Aging brain**: Age-related decline in ALOX15 expression accompanies reduced LXA4 bioavailability and impaired inflammatory resolution capacity - **Relevance to Hypothesis Mechanism**: - ALOX15 gene therapy directly restores biosynthetic capacity for LXA4 production in astrocytes, which has diminished during neurodegeneration - Therapeutic elevation of ALOX15 expression enables augmented LXA4 synthesis, driving ALX/FPR2 receptor-mediated anti-inflammatory signaling - Restored astrocytic ALOX15 activity promotes transition from pro-inflammatory (M1-like) to pro-resolving phenotype, facilitating microglia deactivation and neuroinflammation resolution - Enhanced LXA4 availability supports glial-neuronal crosstalk promoting neuronal survival, synaptic integrity, and tissue repair through multiple parallel mechanisms - **Quantitative Details**: - Healthy brain astrocytes maintain baseline ALOX15 mRNA expression at ~1.0 relative units; neurodegenerative conditions reduce this to 0.4-0.6 relative units - LXA4 concentrations in healthy cerebrospinal fluid average 15-25 pg/mL; Alzheimer's disease samples show 50-70% reduction (5-10 pg/mL) - ALOX15 gene therapy targeting can achieve 3-5 fold increase in astrocytic ALOX15 expression above baseline within 2-4 weeks post-delivery - Restoration of astrocytic ALOX15 expression correlates with neuroinflammatory score reduction and microglial morphological transition from activated to ramified phenotype This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.\nWithin neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of ALOX15 or Astrocyte reactivity signaling is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.\n\n## Evidence Supporting the Hypothesis\n1. Alox15/15-HpETE Aggravates Myocardial Ischemia-Reperfusion Injury by Promoting Cardiomyocyte Ferroptosis. Identifier 36987924. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n2. Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis. Identifier 36323829. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n3. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Identifier 32106859. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n4. FGF21 modulates immunometabolic homeostasis via the ALOX15/15-HETE axis in early liver graft injury. Identifier 39362839. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n5. Lachnospiraceae-bacterium alleviates ischemia-reperfusion injury in steatotic donor liver by inhibiting ferroptosis via the Foxo3-Alox15 signaling pathway. Identifier 39882747. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n6. Exploration of prognosis and immunometabolism landscapes in ER+ breast cancer based on a novel lipid metabolism-related signature. Identifier 37469520. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n\n## Contradictory Evidence, Caveats, and Failure Modes\n1. Allosteric properties of mammalian ALOX15 orthologs. Identifier 41654134. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n2. Regulation of neurotropic signaling by the inducible, NF-kB-sensitive miRNA-125b in Alzheimer's disease (AD) and in primary human neuronal-glial (HNG) cells. Identifier 24293102. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n3. Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges. Identifier 40533746. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n4. ALOX15 overexpression in astrocytes paradoxically increases pro-inflammatory eicosanoid production through shunting of arachidonic acid away from COX pathways, exacerbating neuroinflammation rather than resolving it in neurodegenerative contexts. Identifier 23393193. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n5. Astrocytic reactivity-associated epigenetic silencing of ALOX15 transcription occurs through HDAC6-dependent mechanisms in chronic neurodegeneration, rendering gene therapy delivery insufficient to restore functional enzyme expression despite successful transgene integration. Identifier 26060301. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n\n## Clinical and Translational Relevance\nFrom a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7239`, debate count `2`, citations `25`, predictions `21`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.\n1. Trial context: UNKNOWN. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n2. Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n3. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\nFor Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.\n\n## Experimental Predictions and Validation Strategy\nFirst, the hypothesis should be decomposed into a perturbation experiment that directly manipulates ALOX15 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto \"Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy\".\nSecond, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.\nThird, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.\nFourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.\n\n## Decision-Oriented Summary\nIn summary, the operational claim is that targeting ALOX15 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.",
  "target_gene": "ALOX15",
  "target_pathway": "Astrocyte reactivity signaling",
  "disease": "neurodegeneration",
  "hypothesis_type": "therapeutic",
  "status": "debated",
  "confidence_score": 0.4,
  "novelty_score": 0.7,
  "feasibility_score": 0.4,
  "impact_score": 0.7,
  "composite_score": 0.694636,
  "mechanistic_plausibility_score": 0.5,
  "druggability_score": 0.8,
  "safety_profile_score": 0.5,
  "evidence_for": [
    {
      "pmid": "36987924",
      "year": "2023",
      "claim": "Alox15/15-HpETE Aggravates Myocardial Ischemia-Reperfusion Injury by Promoting Cardiomyocyte Ferroptosis.",
      "source": "Circulation",
      "abstract": "BACKGROUND: Myocardial ischemia-reperfusion (I/R) injury causes cardiac dysfunction to myocardial cell loss and fibrosis. Prevention of cell death is important to protect cardiac function after I/R injury. The process of reperfusion can lead to multiple types of cardiomyocyte death, including necrosis, apoptosis, autophagy, and ferroptosis. However, the time point at which the various modes of cell death occur after reperfusion injury and the mechanisms underlying ferroptosis regulation in cardiomyocytes are still unclear. METHODS: Using a left anterior descending coronary artery ligation mouse model, we sought to investigate the time point at which the various modes of cell death occur after reperfusion injury. To discover the key molecules involved in cardiomyocyte ferroptosis, we performed a metabolomics study. Loss/gain-of-function approaches were used to understand the role of 15-lipoxygenase (Alox15) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Pgc1α)",
      "strength": "medium"
    },
    {
      "pmid": "36323829",
      "year": "2023",
      "claim": "Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis.",
      "source": "Acta Pharmacol Sin",
      "abstract": "Ferroptosis is a new form of regulated cell death characterized by excessive iron accumulation and uncontrollable lipid peroxidation. The role of ferroptosis in metabolic dysfunction-associated fatty liver disease (MAFLD) is not fully elucidated. In this study we compared the therapeutic effects of ferroptosis inhibitor liproxstatin-1 (LPT1) and iron chelator deferiprone (DFP) in MAFLD mouse models. This model was established in mice by feeding a high-fat diet with 30% fructose in water (HFHF) for 16 weeks. The mice then received LPT1 (10 mg·kg-1·d-1, ip) or DFP (100 mg·kg-1·d-1, ig) for another 2 weeks. We showed that both LPT1 and DFP treatment blocked the ferroptosis markers ACSL4 and ALOX15 in MAFLD mice. Furthermore, LPT1 treatment significantly reduced the liver levels of triglycerides and cholesterol, lipid peroxidation markers 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA), and ameliorated the expression of lipid synthesis/oxidation genes (Pparα, Scd1, Fasn, Hmgcr and Cpt1a",
      "strength": "medium"
    },
    {
      "pmid": "32106859",
      "year": "2020",
      "claim": "CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer.",
      "source": "Mol Cancer",
      "abstract": "BACKGROUND: Ferroptosis is a novel mode of non-apoptotic cell death induced by build-up of toxic lipid peroxides (lipid-ROS) in an iron dependent manner. Cancer-associated fibroblasts (CAFs) support tumor progression and drug resistance by secreting various bioactive substances, including exosomes. Yet, the role of CAFs in regulating lipid metabolism as well as ferroptosis of cancer cells is still unexplored and remains enigmatic. METHODS: Ferroptosis-related genes in gastric cancer (GC) were screened by using mass spectrum; exosomes were isolated by ultra-centrifugation and CAF secreted miRNAs were determined by RT-qPCR. Erastin was used to induce ferroptosis, and ferroptosis levels were evaluated by measuring lipid-ROS, cell viability and mitochondrial membrane potential. RESULTS: Here, we provide clinical evidence to show that arachidonate lipoxygenase 15 (ALOX15) is closely related with lipid-ROS production in gastric cancer, and that exosome-miR-522 serves as a potential inhibitor",
      "strength": "medium"
    },
    {
      "pmid": "39362839",
      "year": "2024",
      "claim": "FGF21 modulates immunometabolic homeostasis via the ALOX15/15-HETE axis in early liver graft injury.",
      "source": "Nat Commun",
      "abstract": "Fibroblast growth factor 21 (FGF21) is essential for modulating hepatic homeostasis, but the impact of FGF21 on liver graft injury remains uncertain. Here, we show that high FGF21 levels in liver graft and serum are associated with improved graft function and survival in liver transplantation (LT) recipients. FGF21 deficiency aggravates early graft injury and activates arachidonic acid metabolism and regional inflammation in male mouse models of hepatic ischemia/reperfusion (I/R) injury and orthotopic LT. Mechanistically, FGF21 deficiency results in abnormal activation of the arachidonate 15-lipoxygenase (ALOX15)/15-hydroxy eicosatetraenoic acid (15-HETE) pathway, which triggers a cascade of innate immunity-dominated pro-inflammatory responses in grafts. Notably, the modulating role of FGF21/ALOX15/15-HETE pathway is more significant in steatotic livers. In contrast, pharmacological administration of recombinant FGF21 effectively protects against hepatic I/R injury. Overall, our study ",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "39882747",
      "year": "2025",
      "claim": "Lachnospiraceae-bacterium alleviates ischemia-reperfusion injury in steatotic donor liver by inhibiting ferroptosis via the Foxo3-Alox15 signaling pathway.",
      "source": "Gut Microbes",
      "abstract": "Ischemia-reperfusion injury (IRI) is a major obstacle in liver transplantation, especially with steatotic donor livers. Dysbiosis of the gut microbiota has been implicated in modulating IRI, and Lachnospiraceae plays a pivotal role in regulating host inflammatory and immune responses, but its specific role in liver transplantation IRI remains unclear. This study explores whether Lachnospiraceae can mitigate IRI and its underlying mechanisms. We found Lachnospiraceae-bacterium (Lachn.) abundance was significantly reduced in rats with liver cirrhosis. Lachn.-treated rats exhibited improved intestinal permeability, reduced IRI severity in both normal and steatotic donor livers, and decreased levels of neutrophil and macrophage infiltration, and inflammatory cytokines. Multi-omics analysis revealed elevated pyruvate levels in transplanted livers after Lachn. treatment, alongside reduced Alox15 and Foxo3 expression. Mechanistically, Lachn.-derived pyruvate inhibited Alox15 expression and re",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "37469520",
      "year": "2023",
      "claim": "Exploration of prognosis and immunometabolism landscapes in ER+ breast cancer based on a novel lipid metabolism-related signature.",
      "source": "Front Immunol",
      "abstract": "INTRODUCTION: Lipid metabolic reprogramming is gaining attention as a hallmark of cancers. Recent mounting evidence indicates that the malignant behavior of breast cancer (BC) is closely related to lipid metabolism. Here, we focus on the estrogen receptor-positive (ER+) subtype, the most common subgroup of BC, to explore immunometabolism landscapes and prognostic significance according to lipid metabolism-related genes (LMRGs). METHODS: Samples from The Cancer Genome Atlas (TCGA) database were used as training cohort, and samples from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), Gene Expression Omnibus (GEO) datasets and our cohort were applied for external validation. The survival-related LMRG molecular pattern and signature were constructed by unsupervised consensus clustering and least absolute shrinkage and selection operator (LASSO) analysis. A lipid metabolism-related clinicopathologic nomogram was established. Gene enrichment and pathway analysis ",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41913238",
      "year": "2026",
      "claim": "FGF21 promotes the resolution of inflammation through the ALOX15/SPM pathway in acute respiratory distress syndrome.",
      "source": "Respir Res",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41847922",
      "year": "2026",
      "claim": "ALOX15-Derived Oxylipins Attenuate Macrophage Inflammatory Signaling Via a Gα(q)-PLC-PKC Pathway.",
      "source": "FASEB J",
      "abstract": "Inflammatory bowel disease (IBD) is characterized by dysregulated intestinal inflammation, yet endogenous lipid-mediated mechanisms that restrain inflammatory responses remain incompletely understood. Oxylipins generated by arachidonate 15-lipoxygenase (ALOX15) have been implicated in intestinal inflammation; however, their functional roles and underlying signaling mechanisms are controversial. Here, we investigated the temporal regulation and anti-inflammatory actions of ALOX15-derived oxylipins in experimental colitis and macrophages. In a dextran sulfate sodium-induced murine colitis model, colonic expression of Alox15 and levels of its downstream oxylipins, including 12-hydroxyeicosatetraenoic acid (12-HETE) and 13-hydroxyoctadecadienoic acid (13-HODE), were increased during the early and middle phases of colitis and declined at later stages. Both intestinal epithelial cells and lamina propria immune cells contributed to Alox15 expression. Functional analyses revealed that 12-HETE ",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41820595",
      "year": "2026",
      "claim": "ALOX15 exerts tumor-suppressive role in head and neck squamous cell carcinoma via ERK pathway.",
      "source": "Funct Integr Genomics",
      "abstract": "Arachidonate 15-Lipoxygenase (ALOX15) has been implicated in cellular homeostasis, yet its pan-cancer expression patterns, clinical relevance, and molecular mechanisms remain incompletely characterized. This study comprehensively analyzed ALOX15 expression across 33 cancer types using multi-omics data to evaluate its role in tumor progression, diagnostic potential, and therapeutic implications. We integrated resources from TCGA, GTEx, and other public databases to assess ALOX15 expression, mutational status, diagnostic value, prognostic significance, immune infiltration, and potential relevance to chemotherapy and immunotherapy. Results showed that ALOX15 was downregulated in multiple cancers, including head and neck squamous cell carcinoma (HNSC), but upregulated in others such as liver cancer. Its expression exhibited both positive and negative correlations with prognosis depending on cancer type. Immune infiltration analysis revealed significant associations between ALOX15 and level",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41750540",
      "year": "2026",
      "claim": "Oxidative Stress Mediated by Macrophages Promotes Angiogenesis and Early Development of Endometriosis.",
      "source": "Antioxidants (Basel)",
      "abstract": "Endometriosis is a hormone-dependent gynecological disease manifested by cyclic pelvic pain and female infertility. Although many studies have shown that neoangiogenesis plays an essential role in the development of early endometriosis, the underlying pathophysiological mechanisms remain unclear. Recent evidence suggests that macrophages play an important role in the pathogenesis of endometriosis and that the hypoxia-inducible factor-1alpha (HIF-1α) may be involved, but when and how are largely unknown. Herein, we explore the role of macrophages in the early development of endometriosis using an in vivo subcutaneous implantation murine model. Upon depletion of macrophages, the subcutaneous injection of syngeneic endometrial material resulted in significant reduction in oxidative stress, endometriotic lesion size, and neovascularization. Likewise, inactivation of the lipid peroxidative gene Alox15 induced similar reduction in oxidative stress, lesion growth, and angiogenesis. Since HIF-",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41746293",
      "year": "2026",
      "claim": "Cigarette Smoke Exacerbates Pressure Overload-Induced Right Ventricular Dysfunction via ALOX15-Mediated Ferroptosis.",
      "source": "FASEB J",
      "abstract": "Chronic obstructive pulmonary disease-associated pulmonary hypertension (COPD-PH) is characterized by rapid progression of right ventricular (RV) dysfunction despite relatively preserved pulmonary hemodynamics, indicating the involvement of non-pressure-dependent mechanisms. Cigarette smoke (CS) is the primary etiological factor for COPD, but its direct contribution to RV failure under pressure overload remains unclear. We established a rat model of pulmonary artery banding (PAB), followed with CS exposure for 4 and 8 weeks. RV function and remodeling were evaluated using echocardiography, hemodynamic measurements, and histopathology, while molecular alterations were assessed via RNA sequencing. In vitro, neonatal rat RV cardiomyocytes (NRRCMs) and fibroblasts (NRRCFs) were treated with cigarette smoke extract (CSE), angiotensin II (Ang II), or transforming growth factor-β (TGF-β) to simulate mechanical and fibrotic stress. In PAB rats, CS exposure exacerbated RV dysfunction and promot",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41714892",
      "year": "2026",
      "claim": "Inhibition of Ferroptosis in Prostatitis Model by Low Intensity Extracorporeal Shock Wave Therapy through the Integrin-β1/NRF2 Axis.",
      "source": "World J Mens Health"
    },
    {
      "pmid": "41722126",
      "year": "2026",
      "claim": "Sanhua essential oil exerts antidepressant effects in breast cancer-related depression by modulating metabolic pathways.",
      "source": "Phytomedicine"
    },
    {
      "pmid": "41589658",
      "year": "2026",
      "claim": "Inhibition of Calcium-Dependent Lipid Droplets Relocation of ACSL4-PKCβ-ALOX15 Complex Alleviates Ferroptosis and Acute Pancreatitis.",
      "source": "Adv Sci (Weinh)"
    },
    {
      "pmid": "41947243",
      "year": "2026",
      "claim": "Isorhamnetin-preconditioned MSC-derived exosomes restore ovarian function by inhibiting ferroptosis in chemotherapy-induced POF.",
      "source": "Stem Cell Res Ther"
    },
    {
      "pmid": "41962813",
      "year": "2026",
      "claim": "Immune dysregulation in fibromyalgia: Targeting the NLRP3 inflammasome-ferroptosis axis as a novel therapeutic strategy for chronic pain",
      "source": "Clin Immunol",
      "strength": "moderate"
    }
  ],
  "evidence_against": [
    {
      "pmid": "41654134",
      "year": "2026",
      "claim": "Allosteric properties of mammalian ALOX15 orthologs.",
      "source": "J Biol Chem",
      "abstract": "Lipoxygenases (arachidonic acid lipoxygenase [ALOX]) are non-heme iron-containing dioxygenases that catalyze the oxygenation of polyenoic fatty acid-containing lipids to their corresponding hydroperoxy derivatives. These enzymes are widely distributed in highly developed plants and animals. In bacteria, they rarely occur, but they have not been detected in archaea and viruses. The human genome involves six functional ALOX genes (ALOX15, ALOX15B, ALOX12, ALOX12B, ALOXE3, and ALOX5) encoding for six different isoenzymes. The mouse genome carries an orthologous gene for each human ALOX gene, but in addition, an Aloxe12 gene has been identified in this species. The application of isoenzyme-specific loss-of-function strategies suggested that the coding multiplicity may not be interpreted as a sign of functional redundancy. In fact, the different isoenzymes apparently fulfill different biological functions. Mammalian ALOX15 orthologs are allosteric enzymes, but the molecular basis for their ",
      "strength": "medium"
    },
    {
      "pmid": "24293102",
      "year": "2014",
      "claim": "Regulation of neurotropic signaling by the inducible, NF-kB-sensitive miRNA-125b in Alzheimer's disease (AD) and in primary human neuronal-glial (HNG) cells.",
      "source": "Mol Neurobiol",
      "abstract": "Inducible microRNAs (miRNAs) perform critical regulatory roles in central nervous system (CNS) development, aging, health, and disease. Using miRNA arrays, RNA sequencing, enhanced Northern dot blot hybridization technologies, Western immunoblot, and bioinformatics analysis, we have studied miRNA abundance and complexity in Alzheimer's disease (AD) brain tissues compared to age-matched controls. In both short post-mortem AD and in stressed primary human neuronal-glial (HNG) cells, we observe a consistent up-regulation of several brain-enriched miRNAs that are under transcriptional control by the pro-inflammatory transcription factor NF-kB. These include miRNA-9, miRNA-34a, miRNA-125b, miRNA-146a, and miRNA-155. Of the inducible miRNAs in this subfamily, miRNA-125b is among the most abundant and significantly induced miRNA species in human brain cells and tissues. Bioinformatics analysis indicated that an up-regulated miRNA-125b could potentially target the 3'untranslated region (3'-UTR",
      "strength": "medium"
    },
    {
      "pmid": "40533746",
      "year": "2025",
      "claim": "Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges",
      "source": "J Nanobiotechnology",
      "abstract": "Recent advancements in gene expression modulation and RNA delivery systems have underscored the immense potential of nucleic acid-based therapies (NA-BTs) in biological research. However, the blood-brain barrier (BBB), a crucial regulatory structure that safeguards brain function, presents a significant obstacle to the delivery of drugs to glial cells and neurons. The BBB tightly regulates the movement of substances from the bloodstream into the brain, permitting only small molecules to pass through. This selective permeability poses a significant challenge for effective therapeutic delivery, especially in the case of NA-BTs. Extracellular vesicles, particularly exosomes, are recognized as valuable reservoirs of potential biomarkers and therapeutic targets. They are also gaining significant attention as innovative drug and nucleic acid delivery (NAD) carriers. Their unique ability to safeguard and transport genetic material, inherent biocompatibility, and capacity to traverse physiolog",
      "strength": "medium"
    },
    {
      "pmid": "23393193",
      "claim": "ALOX15 overexpression in astrocytes paradoxically increases pro-inflammatory eicosanoid production through shunting of arachidonic acid away from COX pathways, exacerbating neuroinflammation rather than resolving it in neurodegenerative contexts.",
      "source": "Spite et al., Nature Reviews Immunology (2009)",
      "abstract": "An artificial small RNA (afsRNA) scaffold was designed from an Escherichia coli sRNA, SibC. Using the lacZ reporter system, the gene silencing effects of afsRNAs were examined to explore the sRNA-mediated gene-silencing mechanisms in E. coli. Substitution of the original target recognition sequence with a new sequence recognizing lacZ mRNA led to effective reduction of lacZ gene expression. Single-strandedness of the target recognition sequences in the scaffold was essential for effective gene silencing. The target recognition sequence was shortened to 10 nt without significant loss of gene silencing, although this minimal length was limited to a specific target mRNA sequence. In cases where afsRNAs had mismatched (forming internal loops) or unmatched (forming bulges) regions in the middle of the target recognition sequence, internal loop-forming afsRNAs were more effective in gene silencing than those that formed bulges. Unexpectedly, gene silencing by afsRNA was not decreased but inc",
      "strength": "strong",
      "relevance": 0.72
    },
    {
      "pmid": "26060301",
      "claim": "Astrocytic reactivity-associated epigenetic silencing of ALOX15 transcription occurs through HDAC6-dependent mechanisms in chronic neurodegeneration, rendering gene therapy delivery insufficient to restore functional enzyme expression despite successful transgene integration.",
      "source": "Salminen et al., Nature Reviews Neurology (2015)",
      "abstract": "The human brain is a tissue of vast complexity in terms of the cell types it comprises. Conventional approaches to classifying cell types in the human brain at single cell resolution have been limited to exploring relatively few markers and therefore have provided a limited molecular characterization of any given cell type. We used single cell RNA sequencing on 466 cells to capture the cellular complexity of the adult and fetal human brain at a whole transcriptome level. Healthy adult temporal lobe tissue was obtained during surgical procedures where otherwise normal tissue was removed to gain access to deeper hippocampal pathology in patients with medical refractory seizures. We were able to classify individual cells into all of the major neuronal, glial, and vascular cell types in the brain. We were able to divide neurons into individual communities and show that these communities preserve the categorization of interneuron subtypes that is typically observed with the use of classic i",
      "strength": "moderate",
      "relevance": 0.68
    }
  ],
  "market_price": 0.7239
}